Cancer Research and Treatment

Original Articles

General

Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial: Yaewon Yang, Jang-Hee Hahn, Min Seo Kim, Minkwan Jo, Yong-Pyo Lee, Hongsik Kim, Hee Kyung Kim, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2024;56(4):1050-1057. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.080

Abstract PDF Supplementary Material PubReader ePub: Purpose
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are relatively common toxicities that interfere with the quality of life (QoL) of patients with cancer. Anti-inflammatory tripeptide cream (ATPC) is a complex formulation of anti-inflammatory tripeptides, the CD99-agonist Binterin and the Wnt-antagonist Winhibin. The present study aimed to assess the therapeutic effects of ATPC in HFS/HFSR associated with anticancer drugs.
Materials and Methods
This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to 9 weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
Results
Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
Conclusion
Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs.

1,473 View
156 Download

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance: Hee Kyung Kim, Kyung Hee Park, Youjin Kim, Song Ee Park, Han Sang Lee, Sung Won Lim, Jang Ho Cho, Ji-Yeon Kim, Jeong Eon Lee, Jin Seok Ahn, Young-Hyuck Im, Jong Han Yu, Yeon Hee Park; Cancer Res Treat. 2019;51(2):737-747. Published online September 5, 2018; DOI: https://doi.org/10.4143/crt.2018.342

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance.
Materials and Methods
A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.
Results
In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01).
Conclusion
A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.

Citations

Citations to this article as recorded by

PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study
Judith Katharina Ballé, Martina Vetter, Tariku Wakuma Kenea, Pia Eber-Schulz, Christian Reibold, Hannes-Viktor Ziegenhorn, Kathrin Stückrath, Claudia Wickenhauser, Adamu Addissie, Pablo Santos, Eva Johanna Kantelhardt, Sefonias Getachew, Marcus Bauer
BMC Cancer.2024;[Epub] CrossRef
Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Eun Hye Joo, Sangmin Kim, Donghyun Park, Taeseob Lee, Woong-Yang Park, Kyung Yeon Han, Jeong Eon Lee
International Journal of Molecular Sciences.2024; 25(11): 5876. CrossRef
Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer
Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song
Cancer.2024; 130(S8): 1435. CrossRef
Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, Jonathan David Horsnell, Farrokh Pakzad, Tracey Irvine, Polly Partlett, Elizabeth Clayton, Nadine Collins
International Journal of Molecular Sciences.2024; 25(5): 2616. CrossRef
iCluF: an unsupervised iterative cluster-fusion method for patient stratification using multiomics data
Sushil K Shakyawar, Balasrinivasa R Sajja, Jai Chand Patel, Chittibabu Guda, Marieke Kuijjer
Bioinformatics Advances.2024;[Epub] CrossRef
Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification
Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović
Diagnostics.2024; 14(6): 660. CrossRef
Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study
Tobias Berg, Maj-Britt Jensen, Alan Celik, Maj-Lis Talman, Maria Anna Misiakou, Ann Søegaard Knoop, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing
JCI Insight.2024;[Epub] CrossRef
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Katerina S. Grechukhina, Daria A. Filonenko, Margarita V. Sukhova, Liudmila G. Zhukova
Journal of Modern Oncology.2024; 26(2): 182. CrossRef
Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study
Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
BMC Cancer.2024;[Epub] CrossRef
LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer
Deepak Verma, Sumit Siddharth, Ashutosh S. Yende, Qitong Wu, Dipali Sharma
Cells.2024; 13(22): 1918. CrossRef
Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data
Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu
Cells.2023; 12(3): 367. CrossRef
Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes
Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li
IEEE Access.2023; 11: 10912. CrossRef
Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
Thérèse Dix-Peek, Boitumelo P. Phakathi, Eunice J. van den Berg, Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel A. B. Duarte
Breast Cancer Research and Treatment.2023; 199(1): 1. CrossRef
A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer
Mehdi Hamaneh, Yi-Kuo Yu
Cancer Informatics.2023;[Epub] CrossRef
XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data
Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar
Expert Systems with Applications.2023; 225: 120130. CrossRef
XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes
Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, Virendra Kumar, Ajith Abraham, Divya Khanna, Naveen Kumar
Biomedical Signal Processing and Control.2023; 84: 104979. CrossRef
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, Dora Natalini, Alessio Piccolantonio, Pietro Arina, Alessandro Morellato, Ugo Ala, Daniela Taverna, Emilia Turco, Paola Defilippi
Frontiers in Oncology.2023;[Epub] CrossRef
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Coralia Bueno Muiño, Miguel Martín, María del Monte-Millán, José Ángel García-Saénz, Sara López-Tarruella
Cancers.2022; 14(3): 512. CrossRef
Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li
Frontiers in Oncology.2022;[Epub] CrossRef
Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer
Xinyu Ren, Yu Song, Yanna zhang, Huanwen Wu, Longyun Chen, Junyi Pang, Liangrui Zhou, Songjie Shen, Zhiyong Liang
BMC Cancer.2022;[Epub] CrossRef
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina
International Journal of Molecular Sciences.2022; 23(15): 8716. CrossRef
The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?
Felipe Andrés Cordero da Luz, Breno Jeha Araújo, Rogério Agenor de Araújo
Critical Reviews in Oncology/Hematology.2022; : 103781. CrossRef
Prognostic factors and molecular subtypes in young women with breast cancer
Yasmin Shukair, Rafaela Veiga Monteiro
Mastology.2022;[Epub] CrossRef
Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies
Haruko Takahashi, Daisuke Kawahara, Yutaka Kikuchi
Cancers.2022; 14(17): 4080. CrossRef
Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection
Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee
Cancers.2022; 14(17): 4120. CrossRef
Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers
Yingying Xu, Yonghao Liang, Guanghao Yin
Clinical and Translational Oncology.2022; 25(4): 1024. CrossRef
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Anthony Gonçalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sébastien Frenel,
JAMA Network Open.2022; 5(12): e2247154. CrossRef
Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
Frontiers in Oncology.2022;[Epub] CrossRef
PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study
Lin Wang, Qian Li, Vasily N. Aushev, Alfred I. Neugut, Regina M. Santella, Susan Teitelbaum, Jia Chen
Breast Cancer.2021; 28(6): 1235. CrossRef
Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification
Sheetal Rajpal, Manoj Agarwal, Virendra Kumar, Anamika Gupta, Naveen Kumar
IEEE Access.2021; 9: 103347. CrossRef
Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level
Yan Zhang, Denan Zhang, Qingkang Meng, Ziqi Liu, Hongbo Xie, Lei Liu, Fei Xu, Xiujie Chen
BMC Cancer.2021;[Epub] CrossRef
A single-cell and spatially resolved atlas of human breast cancers
Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Lee Roden, Simon Junankar, Kate Harvey, Alma Andersson, Aatish Thennavan, Chenfei Wang, James R. Torpy, Nenad Bartonicek, Taopeng Wang, Ludvig Larsson, Dominik Kaczorowski, Neil I. Weisenfeld, Cedric R. Uytingco, Jen
Nature Genetics.2021; 53(9): 1334. CrossRef
Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method
Junmei Hao, Yan Lyu, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lyu, Wenfeng Zhang, Jianbo Zhang, Xunting Wang, Kuisheng Chen, Jiandi Zhang
Frontiers in Oncology.2021;[Epub] CrossRef
Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma
Danhui Zhao, Xin Fu, Joseph Rohr, Yingmei Wang, Mingyang Li, Xiuming Zhang, Junhui Qin, Mengwei Xu, Chao Li, Guorui Sun, Zhe Wang, Shuangping Guo
Pathology - Research and Practice.2021; 228: 153677. CrossRef
Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets
Stefania Morganti, Giuseppe Curigliano
Expert Review of Precision Medicine and Drug Development.2020; 5(1): 7. CrossRef
MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes
Elise Klæstad, Signe Opdahl, Monica Jernberg Engstrøm, Borgny Ytterhus, Elisabeth Wik, Anna Mary Bofin, Marit Valla
Breast Cancer Research and Treatment.2020; 180(1): 73. CrossRef
Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Liuwen Yu, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, Chuan Wang
Journal of Oncology.2020; 2020: 1. CrossRef
Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape
Seokhyun Yoon, Hye Sung Won, Keunsoo Kang, Kexin Qiu, Woong June Park, Yoon Ho Ko
Cancers.2020; 12(5): 1165. CrossRef
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Zhu Li, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Frontiers in Oncology.2020;[Epub] CrossRef
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer
Lei Lei, Xiao-Jia Wang, Yin-Yuan Mo, Skye Hung-Chun Cheng, Yunyun Zhou
Frontiers in Oncology.2020;[Epub] CrossRef
Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes
Baoai Han, He Zhang, Yuying Zhu, Xingxing Han, Zhiyong Wang, Zicong Gao, Yue Yuan, Ruinan Tian, Fei Zhang, Ruifang Niu
Aging.2020; 12(13): 13318. CrossRef
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park
Breast Cancer Research and Treatment.2020; 184(3): 743. CrossRef
Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification
Regine M Schoenherr, Uliana J Voytovich, Jeffrey R Whiteaker, Vijayakrishna K Gadi, Julie R Gralow, Amanda G Paulovich
Clinical Chemistry.2020; 66(11): 1459. CrossRef
A Topic Modeling Analysis of TCGA Breast and Lung Cancer Transcriptomic Data
Filippo Valle, Matteo Osella, Michele Caselle
Cancers.2020; 12(12): 3799. CrossRef
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease
Giuseppe Viale, Elisabetta Munzone
The Breast.2019; 48: S49. CrossRef

13,288 View
478 Download
48 Web of Science
45 Crossref

Case Report

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer: Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2019;51(1):408-412. Published online May 23, 2018; DOI: https://doi.org/10.4143/crt.2018.138

Abstract PDF Supplementary Material PubReader ePub

Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.

Citations

Citations to this article as recorded by

Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients
Hyunjong Lee, Sujin Seo, Sungho Won, Woong-Yang Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
Scientific Reports.2023;[Epub] CrossRef
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
Xueli Tian, Tingxuan Gu, Mee-Hyun Lee, Zigang Dong
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(1): 188645. CrossRef
Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
Rashidi Dzul Keflee, Kok Hoong Leong, Satoshi Ogawa, Jerome Bignon, Mun Chiang Chan, Kin Weng Kong
Biochemical Pharmacology.2022; 205: 115262. CrossRef
Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer
Zhen Wu, Wei Zhao, Zhen Yang, Yue Ming Wang, Yu Dai, Liang-An Chen
Cancer Management and Research.2021; Volume 13: 2025. CrossRef
Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
Hong-Shuai Li, Guang-Jian Yang, Yan Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, Hayat O. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger, Markus Tiemann, Lukas C. Heukamp, Markus Falk
Cancers.2021; 13(12): 2861. CrossRef
Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
BMB Reports.2021; 54(7): 386. CrossRef
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh
Journal of Medicinal Chemistry.2020; 63(1): 40. CrossRef
Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
Gahyun Kim, Jinho Kim, Hongui Cha, Woong-Yang Park, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Se-Hoon Lee, Seung Hwan Moon
Scientific Reports.2020;[Epub] CrossRef
Afatinib/gefitinib/osimertinib

Reactions Weekly.2019; 1741(1): 16. CrossRef
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Jing Liu, Bo Jin, Hang Su, Xiujuan Qu, Yunpeng Liu
BMC Cancer.2019;[Epub] CrossRef
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
Rashmi R. Shah, Devron R. Shah
Drug Safety.2019; 42(2): 181. CrossRef
A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC
Yuanhao Lv, Tingting Du, Ming Ji, Chunyang Wang, Songwen Lin, Nina Xue, Jing Jin, Heng Xu, Xiaoguang Chen
Journal of Drug Targeting.2018; : 1. CrossRef

9,077 View
457 Download
13 Web of Science
13 Crossref

Original Articles

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea: Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2016;48(4):1382-1388. Published online March 11, 2016; DOI: https://doi.org/10.4143/crt.2015.423

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by

HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
Kamal Saeed, Shewaz Salih
JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11. CrossRef
Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
Breast Cancer Research and Treatment.2021; 187(3): 785. CrossRef
Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
PLOS ONE.2021; 16(12): e0261258. CrossRef
Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
The American Journal of Surgery.2020; 220(6): 1417. CrossRef
Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
Breast Disease.2018; 37(4): 177. CrossRef
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
Journal of Translational Medicine.2018;[Epub] CrossRef
Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
World Journal of Surgical Oncology.2018;[Epub] CrossRef
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
Annals of Surgical Oncology.2017; 24(10): 2881. CrossRef
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
Medicine.2016; 95(44): e5302. CrossRef

12,535 View
154 Download
8 Web of Science
9 Crossref

Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study: Mee-Yon Cho, Joon Mee Kim, Jin Hee Sohn, Mi-Jung Kim, Kyoung-Mee Kim, Woo Ho Kim, Hyunki Kim, Myeong-Cherl Kook, Do Youn Park, Jae Hyuk Lee, HeeKyung Chang, Eun Sun Jung, Hee Kyung Kim, So-Young Jin, Joon Hyuk Choi, Mi Jin Gu, Sujin Kim, Mi Seon Kang, Chang Ho Cho, Moon-Il Park, Yun Kyung Kang, Youn Wha Kim, Sun Och Yoon, Han Ik Bae, Mee Joo, Woo Sung Moon, Dae Young Kang, Sei Jin Chang; Cancer Res Treat. 2012;44(3):157-165. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.157

Abstract PDF PubReader ePub

PURPOSE
As a result of various independently proposed nomenclatures and classifications, there is confusion in the diagnosis and prediction of biological behavior of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A comprehensive nationwide study is needed in order to understand the biological characteristics of GEP-NETs in Korea.
MATERIALS AND METHODS
We collected 4,951 pathology reports from 29 hospitals in Korea between 2000 and 2009. Kaplan-Meier survival analysis was used to determine the prognostic significance of clinicopathological parameters.
RESULTS
Although the GEP-NET is a relatively rare tumor in Korea, its incidence has increased during the last decade, with the most significant increase found in the rectum. The 10-year survival rate for well-differentiated endocrine tumor was 92.89%, in contrast to 85.74% in well differentiated neuroendocrine carcinoma and 34.59% in poorly differentiated neuroendocrine carcinoma. Disease related death was most common in the biliary tract (62.2%) and very rare in the rectum (5.2%). In Kaplan-Meier survival analysis, tumor location, histological classification, extent, size, mitosis, Ki-67 labeling index, synaptophysin expression, lymphovascular invasion, perineural invasion, and lymph node metastasis showed prognostic significance (p<0.05), however, chromogranin expression did not (p=0.148). The 2000 and 2010 World Health Organization (WHO) classification proposals were useful for prediction of the prognosis of GEP-NET.
CONCLUSION
The incidence of GEP-NET in Korea has shown a remarkable increase during the last decade, however, the distribution of tumors in the digestive system differs from that of western reports. Assessment of pathological parameters, including immunostaining, is crucial in understanding biological behavior of the tumor as well as predicting prognosis of patients with GEP-NET.

Citations

Citations to this article as recorded by

Risk Factor Analysis of Lymph Node Metastasis for Rectal Neuroendocrine Tumors: Who Needs a Radical Resection in Rectal Neuroendocrine Tumors Sized 1–2 cm?
Jin Sun Choi, Min Jung Kim, Rumi Shin, Ji Won Park, Seung Chul Heo, Seung-Yong Jeong, Kyu Joo Park, Seung-Bum Ryoo
Annals of Surgical Oncology.2024; 31(4): 2414. CrossRef
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors
Joo Young Kim, Jisup Kim, Yong-il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Scientific Reports.2024;[Epub] CrossRef
Endoscopic mucosal resection using anchored snare Tip-in versus precut technique for small rectal neuroendocrine tumors
Seung Wook Hong, Dong-Hoon Yang, Yoo Jin Lee, Dong Hoon Baek, Jaeyoung Chun, Hyun Gun Kim, Sung Joo Kim, Seung-Mo Hong, Dae-Seong Myung
The Korean Journal of Internal Medicine.2024; 39(2): 238. CrossRef
Assessing risk stratification in long-term outcomes of rectal neuroendocrine tumors following endoscopic resection: a multicenter retrospective study
Hyun Jin Lee, Yun Seo, Chang Kyo Oh, Ji Min Lee, Hyun Ho Choi, Tae-Geun Gweon, Sung-Hak Lee, Dae Young Cheung, Jin Il Kim, Soo-Heon Park, Han Hee Lee
Scandinavian Journal of Gastroenterology.2024; 59(7): 868. CrossRef
Clinicopathological Characteristics, Survival and Prognostic Factors in Gastrointestinal Large Cell Neuroendocrine Carcinoma
Lele Chang, Xuemei Zhang, Jiaxin Li, Qingwei Li
American Journal of Clinical Oncology.2024; 47(8): 363. CrossRef
Comparison of endoscopic resection therapies for rectal neuroendocrine tumors
Meijiao Lu, Hongxia Cui, Mingjie Qian, Yating Shen, Jianhong Zhu
Minimally Invasive Therapy & Allied Technologies.2024; 33(4): 207. CrossRef
Klinische Bedeutung von neuroendokrinen Tumoren
Philipp E. Hartrampf, Sebastian E. Serfling, Takahiro Higuchi, Jörg Bojunga, Alexander Weich, Rudolf A. Werner
Die Radiologie.2024; 64(7): 536. CrossRef
Mixed neuroendocrine–non-neuroendocrine neoplasm of the bile duct with long-term prognosis after neoadjuvant chemotherapy
Shinya Nakamura, Masahiro Serikawa, Yasutaka Ishii, Yumiko Tatsukawa, Juri Ikemoto, Sayaka Miyamoto, Kenichiro Uemura, Shinya Takahashi, Koji Arihiro, Shiro Oka
Clinical Journal of Gastroenterology.2024; 17(4): 717. CrossRef
Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers
Luigi Asmundo, Francesco Rizzetto, Michael Blake, Mark Anderson, Amirkasra Mojtahed, William Bradley, Anuradha Shenoy-Bhangle, Carlos Fernandez-del Castillo, Motaz Qadan, Cristina Ferrone, Jeffrey Clark, Valentina Ambrosini, Maria Picchio, Paola Mapelli,
Journal of Clinical Medicine.2024; 13(11): 3281. CrossRef
Primary coexisting adenocarcinoma of the colon and neuroendocrine tumor of the duodenum: A case report and review of the literature
Song Fei, Wei-Dong Wu, Han-Shuo Zhang, Shao-Jie Liu, Dan Li, Bo Jin
World Journal of Gastrointestinal Surgery.2024; 16(8): 2724. CrossRef
Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios
Katerina S. Konstantinoff, Ajaykumar C. Morani, Thomas A. Hope, Priya R. Bhosale, Isaac R. Francis, Motoyo Yano, Amir Iravani, Nikolaos A. Trikalinos, Malak Itani
Abdominal Radiology.2023; 48(5): 1843. CrossRef
Is lymphatic invasion of microrectal neuroendocrine tumors an incidental event?: A case report
Jing-Xue Ran, Liang-Bi Xu, Wan-Wei Chen, Hao-Yi Yang, Yan Weng, Yong-Mei Peng
World Journal of Clinical Cases.2023; 11(4): 859. CrossRef
Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs
Hyung Kyu Park, Ghee Young Kwon
Journal of Korean Medical Science.2023;[Epub] CrossRef
Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells
Hirofumi Watanabe, Fumiyoshi Fujishima, Michiaki Unno, Hironobu Sasano, Takashi Suzuki
Pathology - Research and Practice.2023; 244: 154418. CrossRef
Different miRNAs Related to FBXW7 Mutations or High Mitotic Indices Contribute to Rectal Neuroendocrine Tumors: A Pilot Study
Ho Suk Kang, Ha Young Park, Hyun Lim, Il Tae Son, Min-Jeong Kim, Nan Young Kim, Min Jeong Kim, Eun Sook Nam, Seong Jin Cho, Mi Jung Kwon
International Journal of Molecular Sciences.2023; 24(7): 6329. CrossRef
High-Grade Pure Esophageal Neuroendocrine Carcinoma Arising From Barrett’s Mucosa: A Rare Phenomenon
Parth Patel, Eli A Zaher, Hasan Sqour
Cureus.2023;[Epub] CrossRef
Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors
Jisup Kim, Dong-Hoon Yang, HaeSung Jung, HyungJun Cho, Hyeung-Jin Jang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2023; 147(7): 797. CrossRef
Understanding the increasing incidence of neuroendocrine tumors
Surabhi Pathak, Jason S. Starr, Thorvardur Halfdanarson, Mohamad Bassam Sonbol
Expert Review of Endocrinology & Metabolism.2023; 18(5): 377. CrossRef
Pancreatic Neuroendocrine Tumor (Pan-NET) Presented by Abdominal Pain: A Case Report and Literature Review
Matteo Regolo, Nicolas Cardaci, Clara Salmeri, Alfredo Laudani, Michele Colaci, Massimo Ippolito, Fabio Motta, Salvatore Magrì, Stefanie Parisi, Alfredo Gaetano Torcitto, Lorenzo Malatino
Journal of Clinical Medicine.2023; 12(20): 6617. CrossRef
Clinical Value of Clip-and-Snare Assisted Endoscopic Submucosal Resection in Treatment of Rectal Neuroendocrine Tumors
Xin-Tong Jiang, Yang Hu, Jian Gong, Shi-Bin Guo
Visceral Medicine.2023; 39(5): 140. CrossRef
Clinicopathological characteristics of extrahepatic biliary neuroendocrine neoplasms in the gallbladder, extrahepatic biliary tract, and ampulla of Vater: A single-center cross-sectional study
Young Mok Park, Hyung Il Seo, Byeong Gwan Noh, Suk Kim, Seung Baek Hong, Nam Kyung Lee, Dong Uk Kim, Sung Yong Han
Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(4): 380. CrossRef
Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?
Jack Cope, Raj Srirajaskanthan
Current Oncology Reports.2022; 24(3): 257. CrossRef
Clinicopathologic Characteristics of Gastroenteropancreatic Neuroendocrine Tumors: Experience of a National Referral Hospital in Indonesia
Marini Stephanie, Nur Rahadiani, Hasan Maulahela, Ridho Ardhi Syaiful, Diah Rini Handjari, Ening Krisnuhoni
Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 101. CrossRef
Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms
Daisuke Takayanagi, Hourin Cho, Erika Machida, Atsushi Kawamura, Atsuo Takashima, Satoshi Wada, Takuya Tsunoda, Takashi Kohno, Kouya Shiraishi
Cancers.2022; 14(5): 1119. CrossRef
Neuroendocrine Tumors: a Relevant Clinical Update
Emma N. Rizen, Alexandria T. Phan
Current Oncology Reports.2022; 24(6): 703. CrossRef
A small, low-grade rectal neuroendocrine tumor with lateral pelvic lymph node metastasis: a case report
Seonhui Shin, Young-In Maeng, Seyun Jung, Chun-Seok Yang
Annals of Coloproctology.2022; 38(4): 327. CrossRef
Rectal neuroendocrine neoplasms: what the radiologists should know
Mayur Virarkar, Dheeraj R. Gopireddy, Ajaykumar C. Morani, Ahmad Alkhasawneh, Sergio Piotr Klimkowski, Sindhu Kumar, Chandana Lall, Priya Bhosale
Abdominal Radiology.2022; 47(12): 4016. CrossRef
Risk Factors for Lymph Node Metastasis and Oncologic Outcomes in Small Rectal Neuroendocrine Tumors with Lymphovascular Invasion
Seung-Joo Nam, Byung Chang Kim, Hee Jin Chang, Han Ho Jeon, Junho Kim, Su Young Kim
Gut and Liver.2022; 16(2): 228. CrossRef
Clinical related factors to neuroendocrine tumors in Ecuadorian patients: a logistic biplot approach
Karime Montes Escobar, José Luis Vicente Villardón, Daniel Fabricio Alarcón Cano, Aline Siteneski
Investigación Clínica.2022; 63(1): 19. CrossRef
Clinicopathological Characteristics of Gastroenteropancreatic Neuroendocrine Tumors
Mustafa Şentürk, Berkan Acar, Mehmet Aykut Yildirim, Murat Çakir, Tevfik Küçükkartallar, Celalettin Vatansev
Pancreas.2022; 51(2): 159. CrossRef
Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 – 2015
Tomonobu Koizumi, Kengo Otsuki, Yuriko Tanaka, Shintaro Kanda
BMC Endocrine Disorders.2022;[Epub] CrossRef
State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors
Apostolis Papaefthymiou, Faidon-Marios Laskaratos, Apostolos Koffas, Anastasios Manolakis, Paraskevas Gkolfakis, Sergio Coda, Mikael Sodergren, Noriko Suzuki, Christos Toumpanakis
Current Treatment Options in Oncology.2022; 23(7): 1014. CrossRef
Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population‐based study
Chuyan Chen, Haiyi Hu, Zhibo Zheng, Yi Yang, Wei Chen, Xinwei Qiao, Peng Li, Shutian Zhang
Cancer Medicine.2022; 11(24): 4935. CrossRef
Underwater endoscopic mucosal resection for rectal neuroendocrine tumors (with videos): a single center retrospective study
Haitao Shi, Chuying Wang, Jie Wu, Bin Qin, Jiong Jiang, Na Liu, Yahua Song, Yun Qin, Shiyang Ma
BMC Gastroenterology.2022;[Epub] CrossRef
Endoscopic treatment for rectal neuroendocrine tumor: which method is better?
Seung Min Hong, Dong Hoon Baek
Clinical Endoscopy.2022; 55(4): 496. CrossRef
Clinical outcomes of gastroduodenal neuroendocrine tumors according to their WHO grade: A single-institutional retrospective analysis
Dae Gon Ryu, Su Jin Kim, Cheol Woong Choi, Dae Hwan Kang, Hyung Wook Kim, Su Bum Park, Hyeong Seok Nam, Si Hak Lee, Sun Hwi Hwang
Medicine.2022; 101(37): e30397. CrossRef
Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas
Jing Chen, Yibing Liu, Ke Xu, Fei Ren, Bowen Li, Hong Sun
Frontiers in Oncology.2022;[Epub] CrossRef
Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study
Benjamin E. White, Brian Rous, Kandiah Chandrakumaran, Kwok Wong, Catherine Bouvier, Mieke Van Hemelrijck, Gincy George, Beth Russell, Rajaventhan Srirajaskanthan, John K. Ramage
The Lancet Regional Health - Europe.2022; 23: 100510. CrossRef
The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database
Zhengqi Wu, Xiaotong Qiu, Yao Zhi, Xiaoju Shi, Guoyue Lv
Frontiers in Oncology.2022;[Epub] CrossRef
MODERN PATHOLOGICAL CONSTELLATION FOR GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS AND IMMUNOHISTOCHEMICAL PANEL
P. Vladova
Trakia Journal of Sciences.2022; 20(4): 346. CrossRef
An esophageal submucosal tumor treated with submucosal tunneling endoscopic resection: an unexpected result
Ming-Yan Cai, Mariana Ferreira Cardoso, Yan Zhu, Yun-Shi Zhong, Ping-Hong Zhou
Gastroenterology Report.2021; 9(3): 269. CrossRef
A systematic review of chromogranin A (CgA) and its biomedical applications, unveiling its structure-related functions
Kyuhyung Choi, Manhyuk Han, Seung Joong Kim
Journal of the Korean Physical Society.2021; 78(5): 427. CrossRef
Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor
Min Je Sung, Moon Jae Chung
The Korean Journal of Pancreas and Biliary Tract.2021; 26(1): 24. CrossRef
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Satya Das, Arvind Dasari
Current Oncology Reports.2021;[Epub] CrossRef
Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
Anna La Salvia, Paula Espinosa-Olarte, Maria Del Carmen Riesco-Martinez, Beatriz Anton-Pascual, Rocío Garcia-Carbonero
Cancers.2021; 13(7): 1701. CrossRef
Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
Changhoon Yoo, Chung Ryul Oh, Seung-Tae Kim, Woo Kyun Bae, Hye-Jin Choi, Do-Youn Oh, Myung-Ah Lee, Baek-Yeol Ryoo
Cancer Research and Treatment.2021; 53(2): 291. CrossRef
Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms
Deng Han, Yuan-Liang Li, Zhi-Wei Zhou, Fei Yin, Jie Chen, Fang Liu, Yan-Fen Shi, Wei Wang, Yu Zhang, Xian-Jun Yu, Jian-Ming Xu, Run-Xiang Yang, Chao Tian, Jie Luo, Huang-Ying Tan
World Journal of Gastroenterology.2021; 27(21): 2895. CrossRef
Standardization of the pathologic diagnosis of appendiceal mucinous neoplasms
Dong-Wook Kang, Baek-hui Kim, Joon Mee Kim, Jihun Kim, Hee Jin Chang, Mee Soo Chang, Jin-Hee Sohn, Mee-Yon Cho, So-Young Jin, Hee Kyung Chang, Hye Seung Han, Jung Yeon Kim, Hee Sung Kim, Do Youn Park, Ha Young Park, So Jeong Lee, Wonae Lee, Hye Seung Lee,
Journal of Pathology and Translational Medicine.2021; 55(4): 247. CrossRef
Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma
Hualong Zheng, YaJun Zhao, Qingliang He, Hankun Hao, Yantao Tian, Bingbing Zou, Lixin Jiang, Xiantu Qiu, Yanbing Zhou, Zhi Li, Yanchang Xu, Gang Zhao, Fangqin Xue, Shuliang Li, Weihua Fu, Yongxiang Li, Xiaojun Zhou, Yong Li, Zhenggang Zhu, Jinping Chen, Z
Gastric Cancer.2021; 24(2): 503. CrossRef
Comparative study of laparoscopic versus open radical gastrectomy in advanced gastric neuroendocrine carcinoma: Analysis from a high-volume institution
Ya-Jun Zhao, Lv-Ping Zhuang, Yi-Yang Liu, Ren-Cheng Chen, Jun Zhang, Hai-Xing Zhu, Yong-Cang Wang, Hao You, Ming-Wei Zhang, Xin-Yang He
Asian Journal of Surgery.2020; 43(3): 488. CrossRef
Potential Pitfalls in Diagnostic Digital Image Analysis: Experience with Ki-67 and PHH3 in Gastrointestinal Neuroendocrine Tumors
Sean M Hacking, Sujata Sajjan, Lili Lee, Yonah Ziemba, Mallorie Angert, Yihe Yang, Cao Jin, Hector Chavarria, Nidhi Kataria, Swachi Jain, Mansoor Nasim
Pathology - Research and Practice.2020; 216(3): 152753. CrossRef
Imaging and Contrast-enhanced Ultrasound features of duodenal neuroendocrine tumor: A case report
Yan-Qun Zhang, Jie-Xian Wen, Rong-Kui Luo, Hai-Xia Yuan, Wen-Ping Wang
Clinical Hemorheology and Microcirculation.2020; 76(1): 27. CrossRef
Rare cancers are not rare in Asia as well: The rare cancer burden in East Asia
Tomohiro Matsuda, Young-Joo Won, RuRu Chun-ju Chiang, Jiwon Lim, Kumiko Saika, Keisuke Fukui, Wen-Chung Lee, Laura Botta, Alice Bernasconi, Annalisa Trama
Cancer Epidemiology.2020; 67: 101702. CrossRef
Islet Tumors
Tiffany J. Sinclair, George A. Poultsides
Advances in Surgery.2020; 54: 69. CrossRef
Primary Large Cell Neuroendocrine Carcinoma of the Esophagus Disguised as a Food Impaction
Harsh D. Patel, Jared Beck, Archish Kataria, Glenn W. Gross, Juan Echavarria
ACG Case Reports Journal.2020; 7(6): e00384. CrossRef
Pancreatic nodule positive for 68-Ga-DOTAPEPTIDE-PET: NET or ectopic spleen? The importance of a good differential diagnosis
Francesco Serra, Gianluca De Matteis, Sara Delfanti, Monica Feltri, Alessandro Vanoli, Giorgio Cavenaghi, Anna Gallotti, Marcello Maestri, Silvia Brugnatelli
Clinical and Translational Imaging.2020; 8(5): 307. CrossRef
Gastric neuroendocrine tumor with Helicobacter pylori-associated chronic gastritis
Giovanni Serio, Armando Dell’Anna, Anna Debenedittis, Elisa Stasi, Maria Arcangela Cascarano
International Journal of Surgery Case Reports.2020; 75: 361. CrossRef
Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis
Jisup Kim, Joo Young Kim, Eun Hye Oh, Changhoon Yoo, In Ja Park, Dong-Hoon Yang, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
American Journal of Surgical Pathology.2020; 44(11): 1496. CrossRef
Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours
Yuan-Liang Li, Xu-Dong Qiu, Jie Chen, Yu Zhang, Jie Li, Jian-Ming Xu, Chao Wang, Zhi-Rong Qi, Jie Luo, Huang-Ying Tan
World Journal of Gastrointestinal Oncology.2020; 12(12): 1416. CrossRef
Clinicopathological Study of 100 Cases of Neuroendocrine Neoplasms of the Gastroenteropancreatic System: A Tertiary Cancer Center Experience
Satarupa Tarak Nath Samanta, Shailee Paresh Bhai Mehta, Trupti S Patel, Dhaval H Jetly
Indian Journal of Medical and Paediatric Oncology.2020; 41(03): 340. CrossRef
Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification
Haihong Wang, Yaobing Chen, Guoliang Pi, Ying Zhu, Shengli Yang, Hong Mei, Zhenyu Lin, Tao Zhang
Oncology Letters.2020;[Epub] CrossRef
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis
Junho Kang, Changhoon Yoo, Hee-Sang Hwang, Seung-Mo Hong, Kyu-pyo Kim, Sun Young Kim, Yong-Sang Hong, Tae Won Kim, Baek-Yeol Ryoo
Investigational New Drugs.2019; 37(4): 763. CrossRef
A rare rarity: Neuroendocrine tumor of the esophagus
Elisa Giannetta, Valentina Guarnotta, Francesca Rota, Federica de Cicco, Federica Grillo, Annamaria Colao, Antongiulio Faggiano
Critical Reviews in Oncology/Hematology.2019; 137: 92. CrossRef
Preoperative diagnosis of well‐differentiated neuroendocrine tumor in common hepatic duct by brush cytology: A case report
Jiwoon Choi, Kyong Joo Lee, Sung Hoon Kim, Mee‐Yon Cho
Diagnostic Cytopathology.2019; 47(7): 720. CrossRef
Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors
Chang Min Cho
The Korean Journal of Gastroenterology.2019; 73(3): 124. CrossRef
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
Min-Wei Yang, Xue-Liang Fu, Yong-Sheng Jiang, Xiao-Jing Chen, Ling-Ye Tao, Jian-Yu Yang, Yan-Miao Huo, Wei Liu, Jun-Feng Zhang, Pei-Feng Liu, Qiang Liu, Rong Hua, Zhi-Gang Zhang, Yong-Wei Sun, De-Jun Liu
World Journal of Gastroenterology.2019; 25(14): 1684. CrossRef
Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors
Kira Oleinikov, Alain Dancour, Julia Epshtein, Ariel Benson, Haggi Mazeh, Ilanit Tal, Shay Matalon, Carlos A Benbassat, Dan M Livovsky, Eran Goldin, David J Gross, Harold Jacob, Simona Grozinsky-Glasberg
The Journal of Clinical Endocrinology & Metabolism.2019; 104(7): 2637. CrossRef
Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single‐center study
Lijie Song, Xuejia Zhai, Shunli Yu, Yihui Ma, Feng Wang, Xuxu Yu, Shuang Tao, Yujin Lian, Minjie Yang, Weili Tao, Qingxia Fan
Cancer Medicine.2019; 8(8): 3729. CrossRef
Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors
Louis de Mestier, Diane Lorenzo, Caroline Fine, Jérôme Cros, Olivia Hentic, Thomas Walter, Yves Panis, Anne Couvelard, Guillaume Cadiot, Philippe Ruszniewski
Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(5): 101293. CrossRef
Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review
Francesco Lancellotti, Luca Sacco, Saverio Cerasari, Vittoria Bellato, Simone Cicconi, Antonio Ciardi, Edoardo Maria Muttillo, Tiziana Feola, Roberto Caronna, Piero Chirletti
World Journal of Surgical Oncology.2019;[Epub] CrossRef
Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility
Zhiyan Fu, Chunlai Zuo, Christine E. Sheehan, Deepa T. Patil, Jingmei Lin, Zhaohai Yang, Hwajeong Lee
Applied Immunohistochemistry & Molecular Morphology.2019; 27(6): 454. CrossRef
Duodenal neuroendocrine tumors
A. V. Alekberzade, N. N. Krylov, T. N. Garmanova, R. Shahbazov, F. Azari, K. S. Zuykova, E. D. Litovchenko
Khirurgiya. Zhurnal im. N.I. Pirogova.2019; (7): 87. CrossRef
[68Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications
Elisabetta Giovannini, Giampiero Giovacchini, Elisa Borsò, Patrizia Lazzeri, Mattia Riondato, Rossella Leoncini, Valerio Duce, Andrea Ciarmiello
Current Radiopharmaceuticals.2019; 12(1): 11. CrossRef
Multifocal G1-G2 gastric neuroendocrine tumors: Differentiating between Type I, II and III, a clinicopathologic review
Khaled Algashaamy, Monica Garcia-Buitrago
World Journal of Clinical Cases.2019; 7(17): 2413. CrossRef
Establishment and characterization of a novel neuroendocrine carcinoma cell line derived from a human ascending colon tumor
Seiichi Shinji, Norihiko Sasaki, Takeshi Yamada, Michihiro Koizumi, Ryo Ohta, Akihisa Matsuda, Yasuyuki Yokoyama, Goro Takahashi, Masahiro Hotta, Keisuke Hara, Kohki Takeda, Koji Ueda, Sho Kuriyama, Toshiyuki Ishiwata, Yoshibumi Ueda, Takashi Murakami, Yo
Cancer Science.2019; 110(12): 3708. CrossRef
Gastric neuroendocrine tumors
A. V. Alekberzade, N. N. Krylov, E. M. Lipnitskiy, R. O. Shakhbazov, F. Azari
Khirurgiya. Zhurnal im. N.I. Pirogova.2019; (12): 111. CrossRef
Resectability of Rectal Neuroendocrine Tumors Using Endoscopic Mucosal Resection with a Ligation Band Device and Endoscopic Submucosal Dissection
Hong Kyu Lim, Seong Jun Lee, Dong Hoon Baek, Do Youn Park, Bong Eun Lee, Eun Young Park, Joon Woo Park, Gwang Ha Kim, Geun Am Song
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef
Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia
David Wyld, Mark H. Wan, Julie Moore, Nathan Dunn, Philippa Youl
Cancer Epidemiology.2019; 63: 101598. CrossRef
Lymphovascular invasion as a prognostic value in small rectal neuroendocrine tumor treated by local excision: A systematic review and meta-analysis
Ho Suk Kang, Mi Jung Kwon, Tae-Hwan Kim, Junhee Han, Young-Su Ju
Pathology - Research and Practice.2019; 215(11): 152642. CrossRef
Gastroenteropancreatic Neuroendocrine Tumor with Hepatic Metastasis Misdiagnosed as Hepatocellular Carcinoma
Seul Ki Kim, Sang Chul Kim, Seok Gyo Seo, Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
The Korean Journal of Medicine.2019; 94(5): 449. CrossRef
Clinicopathologic Characteristics and Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasm in a Multi-Ethnic Asian Institution
Wai Meng Tai, Sze Huey Tan, Damien Meng Yew Tan, Kelvin Siu Hoong Loke, David Chee Eng Ng, Sean Xuexian Yan, Jacqueline Siok Gek Hwang, Kiat Hon Lim, Lih Ming Loh, Peng Chin Kek, Brian Kim Poh Goh, Ser Yee Lee, Alexander Yaw Fui Chung, Simon Yew Kuang Ong
Neuroendocrinology.2019; 108(4): 265. CrossRef
Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center
Constantinos Savva, Philip Kaye, Irshad Soomro, Simon L. Parsons, Eleanor James, Srinivasan Madhusudan
Journal of Gastrointestinal Cancer.2018; 49(1): 85. CrossRef
Transanal Endoscopic Microsurgery for Patients with Rare Rectal Tumors
Xin Wu, Guole Lin, Huizhong Qiu, Jiaolin Zhou
Journal of Laparoendoscopic & Advanced Surgical Techniques.2018; 28(5): 546. CrossRef
A case of small intestinal neuroendocrine carcinoma diagnosed using double-balloon endoscopy with long-term survival
Seiji Kawano, Yuichi Miyashima, Yoshio Miyabe, Yoshinari Kawai, Toshihiro Murata, Masashi Uda, Toshihiro Inokuchi, Hiroyuki Okada
Clinical Journal of Gastroenterology.2018; 11(3): 240. CrossRef
How should incidental NEN of the pancreas and gastrointestinal tract be followed?
Riccardo Ariotti, Stefano Partelli, Francesca Muffatti, Valentina Andreasi, Francesca Della Sala, Massimo Falconi
Reviews in Endocrine and Metabolic Disorders.2018; 19(2): 139. CrossRef
Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors
Min Jeong Kim, Mi Jung Kwon, Ho Suk Kang, Kyung Chan Choi, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hyoung-Chul Park
BioMed Research International.2018; 2018: 1. CrossRef
A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms
Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao
Scientific Reports.2018;[Epub] CrossRef
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lingaku Lee, Tetsuhide Ito, Robert T. Jensen
Expert Opinion on Pharmacotherapy.2018; 19(8): 909. CrossRef
Pancreatic Neuroendocrine Neoplasms: A Role of Laparoscopy in Surgical Treatment: Review
Jacek Szeliga, Marek Jackowski
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(3): 147. CrossRef
Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
Panpan Zhang, Wei Wang, Ming Lu, Changqing Zeng, Jie Chen, Enxiao Li, Huangying Tan, Wei Wang, Xianjun Yu, Qiyun Tang, Jiemin Zhao, Lin Shen, Jie Li
Cancer Medicine.2018; 7(9): 4361. CrossRef
Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options
Steven D. Colquhoun
Liver Research.2018; 2(2): 92. CrossRef
Endoscopic Treatment Outcome of Rectal Neuroendocrine Tumors Removed by Ligation-assisted Endoscopic Submucosal Resection
Min Geun Gu, Si Hyung Lee
The Korean Journal of Gastroenterology.2018; 72(3): 128. CrossRef
Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population‐based study
Fang‐Xi Tian, Yu‐Qing Cai, Lv‐Ping Zhuang, Ming‐Fang Chen, Zhong‐Biao Xiu, Yi Zhang, Hong Liu, Zhi‐Hong Liu, Guo‐Ping Liu, Chen Zeng, Fei‐Ling Lin, Jing Liu, Si‐Ting Huang, Liang‐Zhi Zhang, Hua‐Yang Lin
Cancer Medicine.2018; 7(11): 5359. CrossRef
Global burden of neuroendocrine tumors and changing incidence in Kentucky
Aman Chauhan, Qian Yu, Neha Ray, Zainab Farooqui, Bin Huang, Eric B. Durbin, Thomas Tucker, Mark Evers, Susanne Arnold, Lowell B. Anthony
Oncotarget.2018; 9(27): 19245. CrossRef
Gastroenteropancreatic neuroendocrine tumor registry study in China
Lin Cong, Wenming Wu, Wenhui Lou, Jinwan Wang, Feng Gu, Jiaming Qian, Jianming Xu, Feng Bi, Sanjun Cai, Chengwei Tang, Yulong He, Jie Zhong, Yupei Zhao
Journal of Pancreatology.2018; 1(1): 35. CrossRef
Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience
Chul-Hyun Lim, In Seok Lee, Byoung Yeon Jun, Jin Su Kim, Yu Kyung Cho, Jae Myung Park, Sang Young Roh, Myung Ah Lee, Sang Woo Kim, Myung-Gyu Choi
The Korean Journal of Internal Medicine.2017; 32(3): 452. CrossRef
Uncommon Anal Neoplasms
Amitesh C. Roy, David Wattchow, David Astill, Simron Singh, Susan Pendlebury, Kirsten Gormly, Eva Segelov
Surgical Oncology Clinics of North America.2017; 26(1): 143. CrossRef
Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors
Wenhao Ge, Dongkai Zhou, Shaoyan Xu, Weilin Wang, Shusen Zheng
International Journal of Surgery.2017; 39: 127. CrossRef
Recent updates on grading and classification of neuroendocrine tumors
Joo Young Kim, Seung-Mo Hong, Jae Y. Ro
Annals of Diagnostic Pathology.2017; 29: 11. CrossRef
Mixed adenoneuroendocrine carcinoma derived from the cystic duct: A case report
Yu-ki Takemoto, Tomoyuki Abe, Hironobu Amano, Keiji Hanada, Akihito Okazaki, Tomoyuki Minami, Tsuyoshi Kobayashi, Masahiro Nakahara, Shuji Yonehara, Hideki Ohdan, Toshio Noriyuki
International Journal of Surgery Case Reports.2017; 39: 29. CrossRef
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
Journal of Pathology and Translational Medicine.2017; 51(4): 388. CrossRef
Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee
Cancer Chemotherapy and Pharmacology.2017; 80(4): 799. CrossRef
Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas
De-Jun Liu, Xue-Liang Fu, Wei Liu, Lu-Ying Zheng, Jun-Feng Zhang, Yan-Miao Huo, Jiao Li, Rong Hua, Qiang Liu, Yong-Wei Sun
World Journal of Gastroenterology.2017; 23(3): 516. CrossRef
Is endoscopic ultrasonography essential for endoscopic resection of small rectal neuroendocrine tumors?
Su Bum Park, Dong Jun Kim, Hyung Wook Kim, Cheol Woong Choi, Dae Hwan Kang, Su Jin Kim, Hyeong Seok Nam
World Journal of Gastroenterology.2017; 23(11): 2037. CrossRef
Predictive Factors for Lymph Node Metastasis and Prognostic Factors for Survival in Rectal Neuroendocrine Tumors
Beonghoon Sohn, Yoomin Kwon, Seung-Bum Ryoo, Inho Song, Yoon-Hye Kwon, Dong Woon Lee, Sang Hui Moon, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park
Journal of Gastrointestinal Surgery.2017; 21(12): 2066. CrossRef
Efficacy of Precut Endoscopic Mucosal Resection for Treatment of Rectal Neuroendocrine Tumors
Hoonsub So, Su Hyun Yoo, Seungbong Han, Gwang-un Kim, Myeongsook Seo, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon
Clinical Endoscopy.2017; 50(6): 585. CrossRef
Gastroenteropancreatic—origin neuroendocrine carcinomas
Yong Gyun Won, Kyung-Jin Seo, Jiyeon Hyeon, Ok Ran Shin, Eundeok Chang, Der Sheng Sun, Hae Sung Won, Yoon Ho Ko, Sae Jung Na, Su Lim Lee, Young Mi Ku, Dong Soo Lee
Medicine.2017; 96(49): e9009. CrossRef
Sex comb on midleg like-2 is a novel specific marker for the diagnosis of gastroenteropancreatic neuroendocrine tumors
Jiao-Jiao Yang, Hua Huang, Ming-Bing Xiao, Feng Jiang, Wen-Kai Ni, Yi-Fei Ji, Cui-Hua Lu, Run-Zhou Ni
Experimental and Therapeutic Medicine.2017; 14(2): 1749. CrossRef
A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china
Jin-Hu Fan, Yu-Qing Zhang, Su-Sheng Shi, Yuan-Jia Chen, Xing-Hua Yuan, Li-Ming Jiang, Shao-Ming Wang, Li Ma, Yu-Tong He, Chang-Yan Feng, Xi-Bin Sun, Qing Liu, Katrina Deloso, Yihebali Chi, You-Lin Qiao
Oncotarget.2017; 8(42): 71699. CrossRef
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
Jie Li, Ming Lu, Zhihao Lu, Zhongwu Li, Yiqiang Liu, Li Yang, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Jifang Gong, Jing Gao, Yan Li, Lin Shen
Oncotarget.2017; 8(15): 25669. CrossRef
Cap-assisted EMR for rectal neuroendocrine tumors: comparisons with conventional EMR and endoscopic submucosal dissection (with videos)
Dong-Hoon Yang, Yangsoon Park, Sang Hyoung Park, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Gastrointestinal Endoscopy.2016; 83(5): 1015. CrossRef
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study
Sven-Petter Haugvik, Eva Tiensuu Janson, Pia Österlund, Seppo W. Langer, Ragnhild Sørum Falk, Knut Jørgen Labori, Lene Weber Vestermark, Henning Grønbæk, Ivar Prydz Gladhaug, Halfdan Sorbye
Annals of Surgical Oncology.2016; 23(5): 1721. CrossRef
Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center
Jeung Hui Pyo, Sung Noh Hong, Byung-Hoon Min, Jun Haeng Lee, Dong Kyung Chang, Poong-Lyul Rhee, Jae Jun Kim, Sun Kyu Choi, Sin-Ho Jung, Hee Jung Son, Young-Ho Kim
Journal of Gastroenterology.2016; 51(12): 1112. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
C. De Divitiis, C. von Arx, A. M. Grimaldi, D. Cicala, F. Tatangelo, A. Arcella, G. M. Romano, E. Simeone, R. V. Iaffaioli, P. A. Ascierto, S. Tafuto
Journal of Translational Medicine.2016;[Epub] CrossRef
Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution
Lin-Jie Guo, Chun-Hui Wang, Cheng-Wei Tang
Asia-Pacific Journal of Clinical Oncology.2016; 12(3): 284. CrossRef
The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution
Seung Tae Kim, Sang Yun Ha, Jeeyun Lee, Sung No Hong, Dong Kyung Chang, Young Ho Kim, Yoon Ah Park, Jung Wook Huh, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Hee Cheol Kim, Young Suk Park
Medicine.2016; 95(19): e3534. CrossRef
Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience
Govind Babu Kanakasetty, Loknatha Dasappa, Kuntegowdanahalli Chinnagiriyappa Lakshmaiah, Mangesh Kamath, Linu Abraham Jacob, Suresh Babu Mallekavu, Lakkavalli Krishnappa Rajeev, Rudresha Antapura Haleshappa, Lokesh Kadabur Nagendrappa, Smitha Carol Saldan
Journal of Oncology.2016; 2016: 1. CrossRef
Endoscopic treatments for rectal neuroendocrine tumors smaller than 16 mm: a meta-analysis
Hai-Ping Zhang, Wei Wu, Sheng Yang, Jun Lin
Scandinavian Journal of Gastroenterology.2016; 51(11): 1345. CrossRef
Lymph node size is not a reliable criterion for predicting nodal metastasis in rectal neuroendocrine tumours
B. C. Kim, Y. E. Kim, H. J. Chang, S. H. Lee, E. G. Youk, D.‐S. Lee, J. B. Lee, E.‐J. Lee, M. J. Kim, D. K. Sohn, J. H. Oh
Colorectal Disease.2016;[Epub] CrossRef
Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors
Jae Hee Cho, Ji Kon Ryu, Si Young Song, Jin-Hyeok Hwang, Dong Ki Lee, Sang Myung Woo, Young-Eun Joo, Seok Jeong, Seung-Ok Lee, Byung Kyu Park, Young Koog Cheon, Jimin Han, Tae Nyeun Kim, Jun Kyu Lee, Sung-Hoon Moon, Hyunjin Kim, Eun Taek Park, Jae Chul Hw
Pancreas.2016; 45(7): 941. CrossRef
Endoscopic Resection for Small Rectal Neuroendocrine Tumors: Comparison of Endoscopic Submucosal Resection with Band Ligation and Endoscopic Submucosal Dissection
Byoung Wook Bang, Jin Seok Park, Hyung Kil Kim, Yong Woon Shin, Kye Sook Kwon, Joon Mee Kim
Gastroenterology Research and Practice.2016; 2016: 1. CrossRef
Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience
Chaoyong Shen, Huijiao Chen, Haining Chen, Yuan Yin, Luyin Han, Jiaju Chen, Sumin Tang, Xiaonan Yin, Zongguang Zhou, Bo Zhang, Zhixin Chen
BMC Gastroenterology.2016;[Epub] CrossRef
The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure
Yoichiro Okubo, Osamu Motohashi, Norisuke Nakayama, Ken Nishimura, Rika Kasajima, Yohei Miyagi, Manabu Shiozawa, Emi Yoshioka, Masaki Suzuki, Kota Washimi, Kae Kawachi, Madoka Nito, Yoichi Kameda, Tomoyuki Yokose
Diagnostic Pathology.2016;[Epub] CrossRef
A Case of Endoscopically Complete Remission of Esophageal Neuroendocrine Tumors by Concurrent Chemoradiation Therapy
Myung Hee Kim, Hyun Yong Jeong, Jae Kyu Seong, Hee Seok Moon, Sun Hyung Kang, Duk Ki Kim
The Korean Journal of Gastroenterology.2016; 68(5): 265. CrossRef
Outcomes after local excision for rectal neuroendocrine tumor
Yoomin Kwon, Seung-Bum Ryoo, Inho Song, Yoon-Hye Kwon, Dong Woon Lee, Sang Hui Moon, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park
Korean Journal of Clinical Oncology.2016; 12(2): 104. CrossRef
Multivariate analysis of metastasis-related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features
Caiyun Tang, Lingqi Gong, Wenli Zou, Jie Zhang, Yuqian Zhou, Xiaoping Wu, Fanggen Lu, Chunhui Ouyang, Xiaowei Liu
Oncology Reports.2016; 36(6): 3343. CrossRef
Management of gastric and duodenal neuroendocrine tumors
Yuichi Sato, Satoru Hashimoto, Ken-ichi Mizuno, Manabu Takeuchi, Shuji Terai
World Journal of Gastroenterology.2016; 22(30): 6817. CrossRef
Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)
Kaizhou Jin, Jin Xu, Jie Chen, Minhu Chen, Rufu Chen, Ye Chen, Zhiyu Chen, Bin Cheng, Yihebali Chi, Shi-Ting Feng, Deliang Fu, Baohua Hou, Dan Huang, Heguang Huang, Qiang Huang, Jie Li, Ying Li, Houjie Liang, Rong Lin, An'an Liu, Jixi Liu, Xubao Liu, Ming
International Journal of Oncology.2016; 49(5): 1991. CrossRef
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
M. Falconi, B. Eriksson, G. Kaltsas, D.K. Bartsch, J. Capdevila, M. Caplin, B. Kos-Kudla, D. Kwekkeboom, G. Rindi, G. Klöppel, N. Reed, R. Kianmanesh, R.T. Jensen
Neuroendocrinology.2016; 103(2): 153. CrossRef
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis
Tetsuhide Ito, Hisato Igarashi, Kazuhiko Nakamura, Hironobu Sasano, Takuji Okusaka, Koji Takano, Izumi Komoto, Masao Tanaka, Masayuki Imamura, Robert T. Jensen, Ryoichi Takayanagi, Akira Shimatsu
Journal of Gastroenterology.2015; 50(1): 58. CrossRef
Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics
Nurhee Hong, Hyoung Jung Kim, Jae Ho Byun, So Yeon Kim, Kyoung Won Kim, Jin Hee Kim, Seung-Mo Hong
Abdominal Imaging.2015; 40(1): 181. CrossRef
Circumferential submucosal incision prior to endoscopic mucosal resection provides comparable clinical outcomes to submucosal dissection for well-differentiated neuroendocrine tumors of the rectum
Dae Young Cheung, Soo Kyoung Choi, Hyung-Keun Kim, Sung Soo Kim, Hiun-Suk Chae, Kyung Jin Seo, Young-Seok Cho
Surgical Endoscopy.2015; 29(6): 1500. CrossRef
Non-L-cell Immunophenotype and Large Tumor Size in Rectal Neuroendocrine Tumors Are Associated With Aggressive Clinical Behavior and Worse Prognosis
Joo Young Kim, Ki-Suk Kim, Kyung-Jo Kim, In Ja Park, Jong Lyul Lee, Seung-Jae Myung, Yangsoon Park, Young Soo Park, Chang Sik Yu, Jin Cheon Kim, Eunsil Yu, Hyeung-Jin Jang, Seung-Mo Hong
American Journal of Surgical Pathology.2015; 39(5): 632. CrossRef
Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors
Shunda Du, Jianjiao Ni, Linqian Weng, Fei Ma, Shaohua Li, Wenze Wang, Xinting Sang, Xin Lu, Shouxian Zhong, Yilei Mao
Medicine.2015; 94(34): e1429. CrossRef
Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute
Yooju Shin, Sang Yun Ha, Jiyeon Hyeon, Boram Lee, Jeeyun Lee, Kee-Taek Jang, Kyoung-Mee Kim, Young Suk Park, Cheol-Keun Park
Cancer Research and Treatment.2015; 47(4): 738. CrossRef
Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters
Jin Hee Sohn, Mee-Yon Cho, Yangsoon Park, Hyunki Kim, Woo Ho Kim, Joon Mee Kim, Eun Sun Jung, Kyoung-Mee Kim, Jae Hyuk Lee, Hee Kyung Chan, Do Youn Park, Mee Joo, Sujin Kim, Woo Sung Moon, Mi Seon Kang, So-Young Jin, Yun Kyung Kang, Sun Och Yoon, HyeSeung
Cancer Research and Treatment.2015; 47(4): 813. CrossRef
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
Emma Ilett, Seppo Langer, Ingrid Olsen, Birgitte Federspiel, Andreas Kjær, Ulrich Knigge
Diagnostics.2015; 5(2): 119. CrossRef
A Re-evaluation of Colorectal Neuroendocrine Tumors Based on WHO 2010
Akira Watanabe, Mitsuyoshi Ota, Yusuke Suwa, Shinsuke Suzuki, Atsushi Ishibe, Jun Watanabe, Kazuteru Watanabe, Yasushi Ichikawa, Kingo Hirasawa, Mikiko Tanabe, Itaru Endo
Nippon Daicho Komonbyo Gakkai Zasshi.2015; 68(2): 61. CrossRef
Gastroenteropancreatic high‐grade neuroendocrine carcinoma
Halfdan Sorbye, Jonathan Strosberg, Eric Baudin, David S. Klimstra, James C. Yao
Cancer.2014; 120(18): 2814. CrossRef
Mixed Large Cell Neuroendocrine Carcinoma and Adenocarcinoma with Spindle Cell and Clear Cell Features in the Extrahepatic Bile Duct
John Wysocki, Rishi Agarwal, Laura Bratton, Jeremy Nguyen, Mandy Crause Weidenhaft, Nathan Shores, Hillary Z. Kimbrell
Case Reports in Pathology.2014; 2014: 1. CrossRef
Spectrum of Gastroenteropancreatic NENs in Routine Histological Examinations of Bioptic and Surgical Specimen: A Study of 161 Cases Collected from 17 Departments of Pathology in the Czech Republic
Václav Mandys, Tomáš Jirásek
Gastroenterology Research and Practice.2014; 2014: 1. CrossRef
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
Franco Grimaldi, Nicola Fazio, Roberto Attanasio, Andrea Frasoldati, Enrico Papini, Francesco Angelini, Roberto Baldelli, Debora Berretti, Sara Bianchetti, Giancarlo Bizzarri, Marco Caputo, Roberto Castello, Nadia Cremonini, Anna Crescenzi, Maria Vittoria
Journal of Endocrinological Investigation.2014; 37(9): 875. CrossRef
Clinical features and management of type I gastric carcinoids
Yuichi Sato
Clinical Journal of Gastroenterology.2014; 7(5): 381. CrossRef
Diagnosis and Treatment of Rectal Neuroendocrine Tumor
Hyun Deok Shin
Korean Journal of Medicine.2014; 87(4): 415. CrossRef
Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study
Xianbin Zhang, Li Ma, Haidong Bao, Jing Zhang, Zhongyu Wang, Peng Gong
BMC Endocrine Disorders.2014;[Epub] CrossRef
The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea
Chang Geun Lee, Yun Jeong Lim, Seun Ja Park, Byung Ik Jang, Seok Reyol Choi, Jae Kwang Kim, Yong-Tae Kim, Joo Young Cho, Chang Hun Yang, Hoon Jai Chun, Si Young Song
BMC Cancer.2014;[Epub] CrossRef
A Modified Duodenal Neuroendocrine Tumor Staging Schema Better Defines the Risk of Lymph Node Metastasis and Disease-free Survival
Swapnil D. Kachare, Kendall R. Liner, Nasreen A. Vohra, Emmanuel E. Zervos, Timothy L. Fitzgerald
The American Surgeon™.2014; 80(8): 821. CrossRef
A Case of Small Cell Neuroendocrine Tumor Occurring at Hilar Bile Duct
Bum Chul Kim, Tae Jun Song, Hyuk Lee, Mee Joo, Won Ki Bae, Nam-Hoon Kim, Kyung-Ah Kim, June Sung Lee
The Korean Journal of Gastroenterology.2013; 62(5): 301. CrossRef
Neuroendocrine Tumors
Young Suk Park
Korean Journal of Medicine.2013; 85(4): 354. CrossRef
Role of radiotherapy for pancreatobiliary neuroendocrine tumors
Jeongshim Lee, Jinhyun Choi, Chihwan Choi, Jinsil Seong
Radiation Oncology Journal.2013; 31(3): 125. CrossRef
Proposal for a Standardized Pathology Report of Gastroenteropancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Mee-Yon Cho, Jin Hee Sohn, So Young Jin, Hyunki Kim, Eun Sun Jung, Mi-Jung Kim, Kyoung-Mee Kim, Woo Ho Kim, Joon Mee Kim, Yun Kyung Kang, Joon Hyuk Choi, Dae Young Kang, Youn Wha Kim, Eun Hee Choi
Korean Journal of Pathology.2013; 47(3): 227. CrossRef
Multiple Neuroendocrine Tumor of the Distal Ileum
Seung Min Lee, Jong Hoon Lee
The Korean Journal of Gastroenterology.2013; 61(2): 110. CrossRef
The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study
Hui-Jen Tsai, Chun-Chieh Wu, Chia-Rung Tsai, Sheng-Fung Lin, Li-Tzong Chen, Jeffrey S. Chang, Olga Y. Gorlova
PLoS ONE.2013; 8(4): e62487. CrossRef
Which endoscopic treatment is the best for small rectal carcinoid tumors?
Hyun Ho Choi
World Journal of Gastrointestinal Endoscopy.2013; 5(10): 487. CrossRef
Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors
SHUZHENG LIU, YUXI CHANG, JIE MA, XU LI, XIAOHONG LI, JINHU FAN, RONG HUANG, GUANGCAI DUAN, XIBIN SUN
Oncology Letters.2013; 6(6): 1641. CrossRef
Epidemiology of gastroenteropancreatic neuroendocrine tumours
M. Fraenkel, M.K. Kim, A. Faggiano, G.D. Valk
Best Practice & Research Clinical Gastroenterology.2012; 26(6): 691. CrossRef

25,289 View
285 Download
157 Crossref

First
Prev
Page of 1
Next
Last

Search